Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 2, 2011, Pages 99-111

  Chun, Amy W ^a   Freshwater, Robert E ^a   Taft, David R ^a   Gillum, Amanda M ^b   Maniar, Manoj ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b Onconova Therapeutics Inc   (United States)

Author keywords

Ex RAD ; Metabolic stability; Preclinical species; Radioprotectant; Systemic availability

Indexed keywords

EX RAD; ON 01210.NA; RADIOPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RAT; SUSPENSION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MACACA FASCICULARIS; MACACA MULATTA; MALE; MICE; PROTEIN BINDING; RABBITS; RADIATION-PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SULFONAMIDES;

EID: 79952011129     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.741     Document Type: Article

References (24)

1. DHHS, FDA. New drug and biological drug products; Evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Federal Register 2002; 67: 37988-37998.
2. Koenig KL, Goans RE, Hatchett RJ, et al. Medical treatment of radiological casualties: Current concepts. Ann Emerg Med 2005; 45: 643-652. (Pubitemid 40812900)
3. Jarrett DG, Sedlak RG, Dickerson WE, Reeves. GI Medical treatment of radiation injuries - Current US status. Radiat Meas 2007; 42: 1063-1074.
4. Hosseinimehr SJ. Foundation review: Trends in the development of radioprotective agents. Drug Discov Today 2007; 12: 794-805. (Pubitemid 47539965)
5. Vermeulen C, Verwijs-Janssen M, Begg AC, Vens C. Cell cycle phase dependent role of DNA polymerase â in DNA repair and survival after ionizing radiation. Radiother Oncol 2008; 86: 391-398.
6. Fuks Z, Persaud RS, Alfieri A, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994; 154: 2582-2590. (Pubitemid 24173742)
7. Grdina DJ, Murley JS, Kataoka Y. Radioprotectants: Current status and new directions. Oncology 2002; 63(Suppl 2): 2-10.
8. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: The first selective-target and broad-spectrum radio-protector. Oncologist 2007; 12: 738-747. (Pubitemid 47036208)
9. Spencer CM, Goa KL. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radio-protector and cytotoxic chemoprotector. Drugs 1995; 50: 1001-1031.
10. Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf 1999; 21: 367-387.
11. Shaw LM, Bonner HS, Brown DQ. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos 1994; 22: 895-902. (Pubitemid 24377365)
12. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. Semin Oncol 2002; 29: 2-8. (Pubitemid 36173239)
13. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. Effects of dose and schedule on the efficacy of ethyol: preclinical studies. Semin Oncol 2003; 30: 31-39. (Pubitemid 38120497)
14. Lawrence DT, Kirk MA. Chemical terrorism attacks: Update on antidotes. Emerg Med Clin N Am 2007; 25: 567-595. (Pubitemid 46669873)
15. US Food and Drug Administration. Press release: Prussian blue for treating radiation patients. Published October 2003. Available at http://www.fda.gov. Accessed August 2008.
16. Sicherer SH. Risk of severe allergic reactions from the use of potassium iodide for radiation emergencies. J Allergy Clin Immunol 2004; 114: 1395-1397. (Pubitemid 39575896)
17. Kang AD, Cosenza SC, Reddy MVR, Reddy EP. Radioprotection of human bone marrow by ON 01210.Na (Ex-RAD™) through AKT mediated signaling pathway. In 56th Annual Meeting of the Radiation Research Society, Maui, HI, USA, 2010; Abstract #PS173, p73; available from https://timssnet2.allenpress.com/ ECOMRADRES/timssnet/RadeFTP/RRS-2010-Abstract.pdf.
18. Ghosh SP, Kulkarni S, Gambles K, et al. Amelioration of pancytopenia and radiation-induced gastrointestinal damage by Ex-RAD™ in mice. Radiat Res (submitted).
19. Alfieri AA, Liu, L Sharma A, et al. Radiation damage protections by the benzyl styrl sulfone analog, Ex-Rad. Int J Radiat Oncol Biol Phys 2004; 60: S367-S368.
20. Fernandes PP, Maniar M, Dash AK. Development and validation of a sensitive liquid chromatographic method for the analysis of a novel radioprotectant: ON 01210.Na. J Pharm Biomed Anal 2007; 43: 1796-1803. (Pubitemid 46453059)
21. Fernandes P, Maniar M, Dash A. Preformulation development of a parenteral formulation for ON 01210.Na, a radioprotectant. The AAPS Journal 2005; 7(S2), Abstract #T2185; Available from: http://www.aapsj.org/.
22. Ghosh SP, Perkins MW, Hieber K, et al. Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res 2009; 171: 173-179.
23. Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 2008; 25: 2869-2877.
24. Kumar R, Datta K, Moon B-H, Taft DR, Maniar M. Radioprotection and radiomitigation properties of Ex-RAD™ upon oral administration. In 56th Annual Meeting of the Radiation Research Society, Maui, HI, USA, 2010; Abstract #MS701, p46; available from https://timssnet2.allenpress.com/ECOMRADRES/ timssnet/RadeFTP/RRS-2010-Abstract.pdf.